For best experience we recommend to activate Javascript in your browser.

BDS-1

BR, InhA

Catalog No. ABIN2566174

$453.99

Plus shipping costs $50.00

Shipping to: United States

Delivery in 7 to 9 Business Days

Quick Overview for BDS-1 (ABIN2566174)

Application

Blocking Reagent (BR), Inhibition Assay (InhA)

Purpose

BDS-I is a selective blocker of Kv3.4 channel

Sequence

AA sequence: Ala-Ala-Pro-Cys4-Phe-Cys6-Ser-Gly-Lys-Pro -Gly-Arg-Gly-Asp-Leu-Trp-Ile-Leu-Arg-Gly- Thr-Cys22-Pro-Gly-Gly-Tyr-Gly-Tyr-Thr-Ser- Asn-Cys32-Tyr-Lys-Trp-Pro-Asn-Ile-Cys39->Cys40 -Tyr-Pro-His-OH Disulfide bonds: Cys4-Cys39, Cys6-Cys32, Cys22-Cys40

Characteristics

BDS-1 is a 43 amino acid peptide which was originally isolated from the venom of the sea anemona Anemonia Viridis. BDS-1 was originally described as a highly selective blocker of the rapidly inactivating voltage-gated potassium channel Kv3.4/ KCNC4, a potential therapeutic target for major CNS disorders (Alzheimer and Parkinson diseases). The toxin acts as gating modifiers, mainly by shifting the voltage-dependence of activation. Channel block occurs with high affinity (IC50 of 43 nM) and is rapid and reversible. BDS-1 also blocks the Kv3.1 and Kv3.2 channels albeit with a lower affinity (>200 nM). Finally, in a more recent study, it was demonstrated that BDS-1 is a selective gating activator of the Nav1.7 channel subtype, an important target for pain management. On the human isoform, modulation is witnessed by a drastic slowing of channel inactivation which occurs with an IC50 of 3 nM.

Formula

C210H297N57O56S6
Geldanamycin- FITC
Inh 30562-34-6 (4E,6Z,8S,9S,10E,12S,13R,14S,16R)-13-hydroxy-8,14,19-trimethoxy-4,10,12,16-tetramethyl-3,20,22-trioxo-2-azabicyclo[16.3.1] docosa-1(21),4,6,10,18-pentaen-9-yl carbamate

Geldanamycin
Inh 30562-34-6 (4E,6Z,8S,9S,10E,12S,13R,14S,16R)-13-hydroxy-8,14,19-trimethoxy-4,10,12,16-tetramethyl-3,20,22-trioxo-2-azabicyclo[16.3.1] docosa-1(21),4,6,10,18-pentaen-9-yl carbamate

Radicicol
Inh 12772-57-5

Geldanamycin- Biotin
Inh 30562-34-6 (4E,6Z,8S,9S,10E,12S,13R,14S,16R)-13-hydroxy-8,14,19-trimethoxy-4,10,12,16-tetramethyl-3,20,22-trioxo-2-azabicyclo[16.3.1] docosa-1(21),4,6,10,18-pentaen-9-yl carbamate

Herbimycin A
Inh 70563-58-5 [(2R,3S,5S,6R,7S,8E,10S,11S,12E,14E)-2,5,6,11-tetramethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate

17-GMB-APA-GA
Inh [(3R,5S,6R,7S,10S,11S)-21-[3-[4-(2,5-dioxopyrrol-1-yl)butanoylamino]propylamino]-6-hydroxy-5,11-dimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate

TEMPO
Inh 2564-83-2 2,2,6,6-Tetramethylpiperidine 1-oxyl, 2,2,6,6-Tetramethyl-1-piperidinyloxy, free radical, (2,2,6,6-Tetramethyl-1-piperidinyl)oxidanyl, 1,1,5,5-tetramethylpentamethylene nitroxide, 2,2,6,6-Tetramethylpiperidine-1-oxyl

Triacsin C
Inh 76896-80-5 (3E)-1-Oxo-3-[(2E,4E,7E)-2,4,7-undecatrien-1-ylidene]triazane

TPCK
Inh 402-71-1 N-(4-Chloro-3-oxo-1-phenyl-2-butanyl)-4-methylbenzenesulfonamide

Staurosporine
Inh 62996-74-1 (2S,3R,4R,6R)-3-Methoxy-2-methyl-4-(methylamino)-29-oxa-1,7,17-triazaoctacyclo[12.12.2.12,6.07,28.08,13.015,19.020,27.021,26]nonacosa-8,10,12,14,19,21,23,25,27-nonaen-16-one